Platelets Promote Tumor Growth and Metastasis via Direct Interaction between Aggrus/Podoplanin and CLEC-2

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Takagi, Satoshi ^a   Sato, Shigeo ^a   Oh hara, Tomoko ^a   Takami, Miho ^a   Koike, Sumie ^a   Mishima, Yuji ^a   Hatake, Kiyohiko ^a   Fujita, Naoya ^a  

^a CANCER CHEMOTHERAPY CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C TYPE LECTIN LIKE RECEPTOR 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MS 1; PODOPLANIN; THROMBOCYTE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN PC 10; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; FEMALE; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; LUNG SQUAMOUS CELL CARCINOMA; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; SCID MOUSE; THROMBOCYTE AGGREGATION; TUMOR CELL LINE; TUMOR GROWTH; TUMOR XENOGRAFT;

ANIMALS; BLOOD PLATELETS; CHO CELLS; CRICETINAE; CRICETULUS; FEMALE; LECTINS, C-TYPE; MEMBRANE GLYCOPROTEINS; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; NEOPLASM METASTASIS; NEOPLASMS; PROTEIN BINDING;

EID: 84882694049     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0073609     Document Type: Article

References (35)

1. Fidler IJ, (1970) Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2'-deoxyuridine. J Natl Cancer Inst 45: 773-782. PubMed: 5513503.
2. Italiano JE Jr, Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, et al. (2008) Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 111: 1227-1233. PubMed: 17962514.
3. Ho-Tin-Noé B, Goerge T, Cifuni SM, Duerschmied D, Wagner DD, (2008) Platelet granule secretion continuously prevents intratumor hemorrhage. Cancer Res 68: 6851-6858. doi:10.1158/0008-5472.CAN-08-0718. PubMed: 18701510.
4. Ho-Tin-Noé B, Goerge T, Wagner DD, (2009) Platelet: guardians of tumor vasculature. Cancer Res 69: 5623-5626. doi:10.1158/0008-5472.CAN-09-1370. PubMed: 19584268.
5. Gasic GJ, Gasic TB, Stewart CC, (1968) Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci U S A 61: 46-52. doi:10.1073/pnas.61.1.46. PubMed: 5246932.
6. Karpatkin S, Pearlstein E, Salk PL, Yogeeswaran G, (1981) Role of platelets in tumor cell metastasis. Ann N Y Acad Sci 370: 101-118. doi:10.1111/j.1749-6632.1981.tb29726.x. PubMed: 6943955.
7. Kunita A, Kashima TG, Morishita Y, Fukayama M, Kato Y, et al. (2007) The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. Am J Pathol 170: 1337-1347. doi:10.2353/ajpath.2007.060790. PubMed: 17392172.
8. Gay LJ, Felding-Habermann B, (2011) Contribution of platelets to tumour metastasis. Nat Rev Cancer 11: 123-134. doi:10.1038/nrc3004. PubMed: 21258396.
9. Fujita N, Takagi S, (2012) The impact of Aggrus/podoplanin on platelet aggregation and tumour metastasis. J Biochem 152: 407-413. doi:10.1093/jb/mvs108. PubMed: 22992842.
10. Astarita JL, Acton SE, Turley SJ, (2012) Podoplanin: emerging functions in development, the immune system, and cancer. Front Immunol 3: 1-11. PubMed: 22679445.
11. Kato Y, Kaneko M, Sata M, Fujita N, Tsuruo T, et al. (2005) Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumour Biol 26: 195-200. doi:10.1159/000086952. PubMed: 16006773.
12. Shimada Y, Ishii G, Nagai K, Atsumi N, Fujii S, et al. (2009) Expression of podoplanin, CD44, and p63 in squamous cell carcinoma of the lung. Cancer Sci 100: 2054-2059. doi:10.1111/j.1349-7006.2009.01295.x. PubMed: 19681903.
13. Kawase A, Ishii G, Nagai K, Ito T, Nagano T, et al. (2008) Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma. Int J Cancer 123: 1053-1059. doi:10.1002/ijc.23611. PubMed: 18546264.
14. Atsumi N, Ishii G, Kojima M, Sanada M, Fujii S, et al. (2008) Podoplanin, a novel marker of tumor-initiating cells in human squamous cell carcinoma A431. Biochem Biophys Res Commun 373: 36-41. doi:10.1016/j.bbrc.2008.05.163. PubMed: 18539139.
15. Kato Y, Fujita N, Kunita A, Sato S, Kaneko M, et al. (2003) Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. J Biol Chem 278: 51599-515605. doi:10.1074/jbc.M309935200. PubMed: 14522983.
16. Kaneko MK, Kato Y, Kitano T, Osawa M, (2006) Conservation of a platelet activating domain of Aggrus/podoplanin as a platelet aggregation-inducing factor. Gene 378: 52-57. doi:10.1016/j.gene.2006.04.023. PubMed: 16766141.
17. Nakazawa Y, Sato S, Naito M, Kato Y, Mishima K, et al. (2008) Tetraspanin family member CD9 inhibits Aggrus/podoplanin-induced platelet aggregation and suppresses pulmonary metastasis. Blood 112: 1730-1739. doi:10.1182/blood-2007-11-124693. PubMed: 18541721.
18. Suzuki-Inoue K, Kato Y, Inoue O, Kaneko MK, Mishima K, et al. (2007) Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. J Biol Chem 282: 25993-26001. doi:10.1074/jbc.M702327200. PubMed: 17616532.
19. Christou CM, Pearce AC, Watson AA, Mistry AR, Pollitt AY, et al. (2008) Renal cells activate the platelet receptor CLEC-2 through podoplanin. Biochem J 411: 133-140. doi:10.1042/BJ20071216. PubMed: 18215137.
20. Suzuki-Inoue K, Fuller GL, García A, Eble JA, Pöhlmann S, et al. (2006) A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood 107: 542-549. doi:10.1182/blood-2005-05-1994. PubMed: 16174766.
21. Suzuki-Inoue K, (2011) Essential in vivo roles of the platelet activation receptor CLEC-2 in tumour metastasis, lymphangiogenesis and thrombus formation. J Biochem 150: 127-132. doi:10.1093/jb/mvr079. PubMed: 21693546.
22. Suzuki-Inoue K, Inoue O, Ding G, Nishimura S, Hokamura K, et al. (2010) Essential in vivo roles of the C-type lectin receptor CLEC-2: embryonic/neonatal lethality of CLEC-2-deficient mice by blood/lymphatic misconnections and impaired thrombus formation of CLEC-2-deficient platelets. J Biol Chem 285: 24494-24507. doi:10.1074/jbc.M110.130575. PubMed: 20525685.
23. Nakazawa Y, Takagi S, Sato S, Oh-hara T, Koike S, et al. (2011) Prevention of hematogenous metastasis by neutralizing mice and its chimeric anti-Aggrus/podoplanin antibodies. Cancer Sci 102: 2051-2057. doi:10.1111/j.1349-7006.2011.02058.x. PubMed: 21824222.
24. Kaneko MK, Kunita A, Abe S, Tsujimoto Y, Fukayama M, et al. (2012) Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity. Cancer Sci 103: 1913-1919. doi:10.1111/j.1349-7006.2012.02385.x. PubMed: 22816430.
25. Kato Y, Kaneko MK, Kuno A, Uchiyama N, Amano K, et al. (2006) Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain. Biochem Biophys Res Commun 349: 1301-1307. doi:10.1016/j.bbrc.2006.08.171. PubMed: 16979138.
26. Bobek V, Kovarík J, (2004) Antitumor and antimetastatic effect of warfarin and heparins. Biomed Pharmacother 58: 213-219. doi:10.1016/j.biopha.2003.11.007. PubMed: 15183845.
27. Smorenburg SM, Van Noorden CJ, (2001) The complex effects of heparins on cancer progression and metastasis in experimental studies. Pharmacol Rev 53: 93-105. PubMed: 11171940.
28. Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, et al. (2005) The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol 23: 2130-2135. doi:10.1200/JCO.2005.03.134. PubMed: 15699479.
29. Lazo-Langner A, Goss GD, Spaans JN, Rodger MA, (2007) The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials. J Thromb Haemost 5: 729-737. doi:10.1111/j.1538-7836.2007.02427.x. PubMed: 17408406.
30. Thun MJ, Jacobs EJ, Patrono C, (2012) The role of aspirin in cancer prevention. Nat Rev Clin Oncol 9: 259-267. doi:10.1038/nrclinonc.2011.199. PubMed: 22473097.
31. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, et al. (2009) SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 41: 1238-1242. doi:10.1038/ng.465. PubMed: 19801978.
32. Ramos AH, Dutt A, Mermel C, Perner S, Cho J, et al. (2009) Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther 8: 2042-2050. doi:10.4161/cbt.8.21.9764. PubMed: 19755855.
33. The Cancer Genome Atlas Research Network (2012) Comprehensive genomic characterization of squamous cell lung cancers. Nature 489: 519-525.
34. Pintucci G, Froum S, Pinnell J, Mignatti P, Rafii S, et al. (2002) Trophic effects of platelets on cultured endothelial cells are mediated by platelet-associated fibroblast growth factor-2 (FGF-2) and vascular endothelial growth factor (VEGF). Thromb Haemost 88: 834-842. PubMed: 12428103.
35. Cueni LN, Chen L, Zhang H, Marino D, Huggenberger R, et al. (2010) Podoplanin-Fc reduces lymphatic vessel formation in vitro and in vivo and causes disseminated intravascular coagulation when transgenically expressed in the skin. Blood 116: 4376-4384. doi:10.1182/blood-2010-04-278564. PubMed: 20716773.